Jinan Zhuocheng Bio-Tech Co., Ltd.

In veterinary API manufacturing, two distinct production approaches operate side by side. In stainless-steel fermentation tanks, microorganisms convert nutrients into valuable compounds through metabolic processes. In chemical reactors, carefully controlled reactions transform starting materials into target molecules.

Fermentation and chemical synthesis form two major manufacturing routes for veterinary active pharmaceutical ingredients (APIs). Understanding how these approaches differ helps explain the structure of the veterinary pharmaceutical supply chain, as well as the factors that influence production costs, supply stability and product quality.

Fermentation: Harnessing Microorganisms to Produce Active Compounds

Fermentation uses the metabolic capabilities of microorganisms, including bacteria and fungi, to produce specific compounds under controlled conditions. By optimizing strains, nutrients, temperature, pH and other process parameters, manufacturers can improve the yield and consistency of the target substance.

This approach is particularly valuable for complex natural products whose molecular structures can be difficult or uneconomical to reproduce entirely through chemical synthesis.

Macrolide antibiotics are representative examples of fermentation-based manufacturing. Tylosin is produced through microbial fermentation and is widely used in veterinary medicine, particularly in applications involving susceptible bacteria and mycoplasmas. Tilmicosin and tylvalosin are produced through further chemical modification of fermentation-derived starting materials, making them examples of semisynthetic antibiotics.

Doramectin is another fermentation-derived veterinary antiparasitic agent. Like other avermectin-related compounds, it relies on microbial biosynthesis as a key part of its manufacturing process and is used in parasite control in livestock and certain other animal species, subject to product-specific approvals.

Pleuromutilin derivatives also illustrate the importance of fermentation. Valnemulin and tiamulin are produced using pleuromutilin-derived starting materials followed by chemical modification. Fermentation provides the complex core structure, while subsequent chemical steps establish the final molecular structure.

In the anticoccidial segment, polyether ionophore antibiotics such as monensin and salinomycin are produced through microbial fermentation. Milbemycin-related compounds also rely on microbial biosynthesis, with further chemical modification used to produce certain veterinary antiparasitic agents, including milbemycin oxime.

The main advantages of fermentation include the ability to produce structurally complex compounds, the use of renewable feedstocks in many processes and relatively mild reaction conditions. However, fermentation also presents challenges. Production cycles can be long, yields may be difficult to improve, and downstream extraction and purification can be complex. Manufacturing performance depends heavily on strain development and process optimization, which can require substantial investment and long-term technical expertise.

Chemical Synthesis: Building Molecules Through Controlled Reactions

Chemical synthesis follows a different approach. Starting from basic chemicals or pharmaceutical intermediates, manufacturers use a sequence of controlled reactions to construct the target molecule.

For suitable compounds, chemical synthesis can offer predictable reaction pathways, scalable production and precise control over molecular structure and impurity profiles. Its economic performance, however, depends on factors such as raw material prices, reaction yield, solvent consumption, purification requirements and waste treatment costs.

Sulfonamide veterinary drugs are representative examples of chemically synthesized products. Compounds such as sulfachloropyridazine sodium, sulfaquinoxaline sodium and other sulfonamide derivatives are manufactured through multistep chemical processes using appropriate intermediates.

Sulfonamides have a long history in antimicrobial therapy and continue to be used in veterinary medicine for selected bacterial infections and protozoal diseases, depending on the specific compound, target species and approved indication.

Flunixin meglumine, a non-steroidal anti-inflammatory drug used in veterinary medicine, is another example of a product manufactured through chemical synthesis. It is used in certain livestock applications for the management of pain, inflammation and fever in accordance with approved product labeling.

Some veterinary cephalosporins follow a different pattern. Ceftiofur and cefquinome are semisynthetic antibiotics rather than products made entirely by fermentation or wholly chemical synthesis. Their production involves a suitable beta-lactam starting nucleus, followed by chemical modification and other processing steps to obtain the final active ingredient.

Diclazuril, a synthetic anticoccidial agent, and neostigmine methyl sulfate, used in specific veterinary medical applications, are additional examples of products whose manufacturing routes rely primarily on chemical synthesis.

Despite its advantages, chemical synthesis is not always the most economical option. For molecules with highly complex structures, a fully synthetic route may involve numerous reaction steps, low overall yields and costly purification. In such cases, a semisynthetic approach can be more practical: fermentation produces the complex molecular core, and chemical synthesis introduces the required structural modifications.

The Boundary Between Fermentation and Synthesis Is Becoming Less Distinct

In modern veterinary API manufacturing, many products cannot be classified simply as either fermentation-derived or chemically synthesized.

Semisynthesis is a common approach that combines the strengths of both technologies. Fermentation provides a suitable starting compound or molecular core, while chemical reactions modify its structure to achieve the required activity and physicochemical properties.

Tilmicosin, tylvalosin, tiamulin and valnemulin illustrate the importance of this combined approach. Their manufacturing processes depend on both biological production and subsequent chemical transformation.

At the same time, biotechnology is influencing processes traditionally dominated by chemical synthesis. Enzymatic catalysis is being explored for selected intermediates and reaction steps, with the potential to improve selectivity, reduce energy consumption and limit certain waste streams.

Fermentation technology is also advancing through strain engineering and synthetic biology. These tools can help manufacturers improve yields, optimize metabolic pathways and develop more efficient production processes.

As a result, the future of veterinary API manufacturing is unlikely to be defined by a simple choice between fermentation and chemical synthesis. Instead, the focus is shifting toward selecting and integrating the most appropriate technologies for each molecule.

What These Manufacturing Routes Mean for Buyers

For veterinary API buyers, the differences between fermentation and chemical synthesis can affect production economics, supply reliability and quality management.

Fermentation-based products may be influenced by strain performance, fermentation conditions, nutrient costs and downstream recovery efficiency. Changes in these factors can affect yields, production schedules and manufacturing costs.

Chemically synthesized products are generally more directly influenced by the prices and availability of starting materials, reaction efficiency, solvent use and waste treatment requirements. For suitable products, production capacity may be expanded through process optimization and additional equipment, although the time and investment required vary considerably by product.

Neither route is inherently superior in every situation. A fermentation-derived API is not automatically higher quality, and a chemically synthesized API is not necessarily less reliable. Quality depends on the manufacturing process, impurity control, analytical methods, process validation and the effectiveness of the manufacturer's quality management system.

For buyers, supplier evaluation should therefore focus on more than the stated manufacturing route. Important considerations include API specifications, impurity profiles, batch-to-batch consistency, supporting quality documentation, manufacturing capabilities and supply continuity.

Conclusion

Fermentation and chemical synthesis remain two fundamental technologies in veterinary API manufacturing, while semisynthesis connects them into a broader and more flexible production system.

Fermentation enables the production of complex molecules through biological processes. Chemical synthesis provides precise structural modification and scalable manufacturing for a wide range of compounds. Advances in biotechnology and process engineering are creating additional opportunities to combine these approaches more efficiently.

Ultimately, the value of a manufacturing route is determined not by its category alone, but by its ability to deliver safe, effective and consistently high-quality APIs through a reliable and economically sustainable process.